Laquinimod
Laquinimod is an oral drug treatment. It inhibits disease progression although how it does so is not fully understood yet. At present it is at late stage trials.
After 36 weeks of treatment, it was shown that the level of inflammatory disease activity was significantly reduced. The drug seems to be well tolerated and effective.
Treatment over six months resulted in a 30% decrease in MRI activity. Those with disease activity at the start of the study showed a decrease of more than 40%. The only side-effect reported in some patients is temporary increases in liver enzymes.
Approved Use
Laquinimod is not currently approved.
This site is hosted by names.co.uk and the domain name has been registered with them. I have found them to be reasonably priced, helpful and reliable. So, if you are looking for domain name registration or web site hosting, click the above banner.